You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,773,720

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,773,720 protect, and when does it expire?

Patent 6,773,720 protects LIALDA and is included in one NDA.

This patent has thirty-one patent family members in seventeen countries.

Summary for Patent: 6,773,720
Title: Mesalazine controlled release oral pharmaceutical compositions
Abstract:Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, comprising: a) an inner lipophilic matrix consisting of substances with a melting point below C. in which the active ingredient is at least partly inglobated; b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed; c) optionally other excipients.
Inventor(s): Villa; Roberto (Panama, PA), Pedrani; Massimo (Panama, PA), Ajani; Mauro (Panama, PA), Fossati; Lorenzo (Panama, PA)
Assignee: Cosmo S.p.A. (Milan, IT)
Application Number:10/009,491
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,773,720
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Process;

Drugs Protected by US Patent 6,773,720

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa LIALDA mesalamine TABLET, DELAYED RELEASE;ORAL 022000-001 Jan 16, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,773,720

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI99A1316Jun 14, 1999
PCT Information
PCT FiledJune 08, 2000PCT Application Number:PCT/EP00/05321
PCT Publication Date:December 21, 2000PCT Publication Number: WO00/76481

International Family Members for US Patent 6,773,720

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 235234   Start Trial
Austria 324104   Start Trial
Australia 5077200   Start Trial
Canada 2377299   Start Trial
China 100448448   Start Trial
China 1217665   Start Trial
China 1355694   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.